Home Cart Sign in  
Chemical Structure| 2095719-92-7 Chemical Structure| 2095719-92-7

Structure of ASTX029
CAS No.: 2095719-92-7

Chemical Structure| 2095719-92-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ASTX-029 is selective inhibitor of the extracellular signal-regulated kinases 1 and 2 (ERK 1/2) with potential antineoplastic activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ASTX029

CAS No. :2095719-92-7
Formula : C29H31ClFN5O5
M.W : 584.04
SMILES Code : O=C1C=2C(CN1[C@@H](C(N[C@H](CO)C3=CC(OC)=CC(F)=C3)=O)C)=CC=C(C2)C4=NC(NC5CCOCC5)=NC=C4Cl
MDL No. :MFCD32874105
InChI Key :BVRGQPJKSKKGIH-PUAOIOHZSA-N
Pubchem ID :129053037

Safety of ASTX029

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of ASTX029

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04466514 Healthy Volunteers PHASE1 COMPLETED 2020-10-06 Frontage Clinical Services, Se... More >>caucus, New Jersey, 07094, United States Less <<
NCT03520075 Solid Tumor, Adult PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-12-01 City of Hope Comprehensive Can... More >>cer Center, Duarte, California, 91010, United States|University of Southern California Norris Comprehensive Cancer Center Site#114, Los Angeles, California, 90033, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Site# 107, Los Angeles, California, 90048, United States|Hoag Memorial Hospital Site#115, Newport Beach, California, 92658, United States|University of California Davis Medical Center Site #121, Sacramento, California, 95817, United States|California Pacific Medical Center - Sutter Pacific Medical Center Site#117, San Francisco, California, 94115-2378, United States|Smilow Cancer Hospital at Yale New Haven Site#105, New Haven, Connecticut, 06510, United States|Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|The Sidney Kimmel Comprehensive Cancer Center Site#106, Baltimore, Maryland, 21231, United States|Massachusetts General Hospital Site#103, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute Site#104, Boston, Massachusetts, 02215, United States|University of Michigan Rogel Cancer Center Site #113, Ann Arbor, Michigan, 48109, United States|Columbia University Irving Medical Center - Herbert Irving Pavilion Site#112, New York, New York, 10032, United States|Providence Portland Medical Center Site #118, Portland, Oregon, 97223, United States|Oregon Health and Science University Site #122, Portland, Oregon, 97239, United States|University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|The University of Texas MD Anderson Cancer Center Site#111, Houston, Texas, 77030, United States|START - South Texas Accelerated Research Therapeutics, LLC Site# 101, San Antonio, Texas, 78229, United States|Virginia Cancer Specialists Site#102, Fairfax, Virginia, 22031, United States|Centre Léon Bérard Service d'Oncologie Médicale Site#202, Lyon, Rhone-Alpes, 69373, France|H?pital de la Timone Site #201, Marseille, 13005, France|Institut Català d'Oncologia Badalona Site#240, Barcelona, 08028, Spain|Hospital Universitari Vall d'Hebrón Servicio de Oncología, Sala coordinación UITM Site#243, Barcelona, 08035, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, 08916, Spain|Hospital Universitario Dexeus Site#241, Barcelona, 8028, Spain|Clinica Universidad de Navarra Madrid Site #242, Madrid, 28027, Spain|Clínica Universidad de Navarra Site#242, Madrid, 28027, Spain|The Christie NHS Foundation Trust Site#220, Manchester, England, M20 4BX, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust Site #221, Newcastle Upon Tyne, NE7 7DN, United Kingdom|Churchill Hospital Site #224, Oxford, OX3 7LE, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.56mL

1.71mL

0.86mL

17.12mL

3.42mL

1.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories